Skill Checkup: A 53-Year-Old Woman With Dry Cough and a Lung Lesion

John C. Leighton Jr, MD, FACP


September 01, 2022

NGS is a high-throughput, sensitive, specific, and relatively cost-efficient molecular test, and minimally invasive liquid biopsy is increasingly used in cancer treatment for genomic profiling. Using both measures has many advantages over other techniques. Profiling with NGS plus liquid biopsy has been shown to help detect cancer early, effectively identify actionable mutations, and help determine cancer patients' prognoses. With technical advances alongside reductions in cost, it is possible that using both NGS and liquid biopsy as biomarkers will be widely adopted into routine clinical diagnosis and oncogene-targeted treatment decisions.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.